Prestige Consumer Healthcare (NYSE:PBH) Stock Breaks Above 200-Day Moving Average – Here’s Why

by · The Markets Daily

Prestige Consumer Healthcare Inc. (NYSE:PBH – Get Free Report) shares crossed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $50.38 and traded as high as $50.84. Prestige Consumer Healthcare shares last traded at $49.1870, with a volume of 533,924 shares traded.

Analyst Ratings Changes

Several equities analysts have recently commented on PBH shares. Zacks Research upgraded Prestige Consumer Healthcare from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 30th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 22nd. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $67.67.

Get Our Latest Report on PBH

Prestige Consumer Healthcare Price Performance

The firm has a market capitalization of $2.36 billion, a PE ratio of 13.97, a P/E/G ratio of 1.54 and a beta of 0.34. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.99 and a current ratio of 3.23. The stock has a fifty day moving average price of $49.16 and a 200-day moving average price of $50.37.

Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.89 by $0.09. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%. The firm had revenue of $265.71 million during the quarter, compared to analysts’ expectations of $253.02 million. During the same period in the prior year, the business posted $0.90 EPS. The firm’s quarterly revenue was up 6.5% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Sell-side analysts forecast that Prestige Consumer Healthcare Inc. will post 4.56 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd lifted its position in Prestige Consumer Healthcare by 69.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock valued at $35,000 after acquiring an additional 236 shares during the last quarter. Barrow Hanley Mewhinney & Strauss LLC acquired a new stake in Prestige Consumer Healthcare in the second quarter valued at approximately $30,000. Versant Capital Management Inc grew its holdings in Prestige Consumer Healthcare by 47.9% in the second quarter. Versant Capital Management Inc now owns 726 shares of the company’s stock worth $34,000 after purchasing an additional 235 shares during the last quarter. Cornerstone Planning Group LLC purchased a new position in Prestige Consumer Healthcare in the first quarter worth $44,000. Finally, EverSource Wealth Advisors LLC grew its holdings in Prestige Consumer Healthcare by 19.4% in the first quarter. EverSource Wealth Advisors LLC now owns 1,531 shares of the company’s stock worth $91,000 after purchasing an additional 249 shares during the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

(Get Free Report)

Prestige Consumer Healthcare Inc (NYSE: PBH) is a consumer healthcare company that develops, markets and distributes over-the-counter (OTC) products and household health-care brands. Its portfolio includes products for eye care, oral care, gastrointestinal health, pain relief, respiratory health, women’s health, and other everyday health needs.

The company’s brands include Dramamine, Bonine, BC, Goody’s, Clear Eyes, TheraTears, Monistat, Summer’s Eve, Vagisil, Luden’s, Chloraseptic, Compound W, Fleet and Debrox.

Further Reading